Results 1 to 10 of about 159,853 (116)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

Brain Sciences, 2022
Background: Cognitive deficits are common in multiple sclerosis (MS) and affect patients at all stages of the disease, regardless of phenotype. Aims: This literature review focuses the cognitive deficits observed in secondary progressive MS (SPMS). It is
Bruno Brochet, Pierre Clavelou, Gilles Defer, Jérôme De Seze, Céline Louapre, Eloi Magnin, Aurélie Ruet, Catherine Thomas-Anterion, Patrick Vermersch   +8 more
doaj   +3 more sources

P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study [PDF]

EJNMMI Research
Background PET imaging of activated microglia has improved our understanding of the pathology behind disability progression in MS, and pro-inflammatory microglia at ‘smoldering’ lesion rims have been implicated as drivers of disability progression.
Jussi Lehto, Richard Aarnio, Jouni Tuisku, Marcus Sucksdorff, Esa Mikko Koivumäki, Marjo Nylund, Semi Helin, Johan Rajander, Jonathan Danon, Jayson Gilchrist, Michael Kassiou, Vesa Oikonen, Laura Airas   +12 more
doaj   +2 more sources

Extracellular Vesicle-Associated miRNA in Multiple Sclerosis Subtypes: Differential Profiles in Secondary Progressive Disease and the Effect of One-Year Siponimod Treatment [PDF]

Cells
Circulating extracellular vesicle-associated microRNAs (EV-miRNAs) are emerging as promising peripheral biomarkers in multiple sclerosis (MS). This prospective, observational pilot study was conceived as a hypothesis-generating investigation to ...
Oana Vrînceanu, Smaranda Maier, Doina Manu, Claudia Bănescu, Rodica Bălașa   +4 more
doaj   +2 more sources

Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. [PDF]

Mult Scler, 2022
W Koch M, Mostert J, Repovic P, Bowen JD, Strijbis E, Uitdehaag B, Cutter G.   +6 more
europepmc   +2 more sources

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2021
The process of neurodegeneration in multiple sclerosis (MS) remains an urgent problem of modern neurology; from the point of view of its therapy, it is especially important to identify this condition during the transition to secondary progression.
D. S. Kasatkin, N. V. Khachanova, V. M. Alifirova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaya, E. P. Evdoshenko, S. A. Sivertseva   +8 more
doaj   +1 more source

Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. [PDF]

PLoS ONE, 2016
Conduction along the optic nerve is often slowed in multiple sclerosis (MS). This is typically assessed by measuring the latency of the P100 component of the Visual Evoked Potential (VEP) using electroencephalography.
Hanni S M Kiiski, Sinéad Ní Riada, Edmund C Lalor, Nuno R Gonçalves, Hugh Nolan, Robert Whelan, Róisín Lonergan, Siobhán Kelly, Marie Claire O'Brien, Katie Kinsella, Jessica Bramham, Teresa Burke, Seán Ó Donnchadha, Michael Hutchinson, Niall Tubridy, Richard B Reilly   +15 more
doaj   +1 more source

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. Objective Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary ...
Dana Horáková, Aaron Boster, Antonio Bertolotto, Mark S Freedman, Isabel Firmino*, Steven J Cavalier, Alan K Jacobs*, Karthinathan Thangavelu*, Nadia Daizadeh, Elizabeth M Poole*, Darren P Baker, David H Margolin*, Tjalf Ziemssen,   +13 more
doaj   +1 more source

Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. [PDF]

PLoS ONE, 2012
To determine whether retinal axonal loss is detectable in patients with a clinically isolated syndrome (CIS), a first clinical demyelinating attack suggestive of multiple sclerosis (MS), and examine patterns of retinal axonal loss across MS disease ...
Jeffrey M Gelfand, Douglas S Goodin, W John Boscardin, Rachel Nolan, Ami Cuneo, Ari J Green   +5 more
doaj   +1 more source

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. [PDF]

PLoS ONE, 2015
Multiple Sclerosis is more common in women than men and females have more relapses than men. In a large international cohort we have evaluated the effect of gender on disability accumulation and disease progression to determine if male MS patients have a
Karen Ann Ribbons, Patrick McElduff, Cavit Boz, Maria Trojano, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Francois Grand'Maison, Raymond Hupperts, Pierre Grammond, Celia Oreja-Guevara, Thor Petersen, Roberto Bergamaschi, Giorgio Giuliani, Michael Barnett, Vincent van Pesch, Maria-Pia Amato, Gerardo Iuliano, Marcela Fiol, Mark Slee, Freek Verheul, Edgardo Cristiano, Ricardo Fernandez-Bolanos, Maria-Laura Saladino, Maria Edite Rio, Jose Cabrera-Gomez, Helmut Butzkueven, Erik van Munster, Leontien Den Braber-Moerland, Daniele La Spitaleri, Alessandra Lugaresi, Vahid Shaygannejad, Vahid Shaygannejad, Orla Gray, Norma Deri, Raed Alroughani, Jeannette Lechner-Scott   +36 more
doaj   +1 more source

Can we treat secondary progressive multiple sclerosis now?

Annals of Indian Academy of Neurology, 2019
Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic ...
Rohit Bhatia, Nishita Singh
doaj   +1 more source